Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study

Original research
par
Meyer, Maximilian et al

Date de publication

2023

Géographie

Switzerland

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Oui

Évalué par des pairs

Yes

L’objectif

This cross-sectional study investigates the impact of benzodiazepine (BZD) use in opioid agonist treatment (OAT) patients on their quality of life (QoL).

Constatations/points à retenir

The association of lower QoL and BZD use in OAT patients is strongly confounded by co-occurring depressive state and psychiatric symptoms.

La conception ou méthodologie de recherche

Survey using a convenience sample (n=141)

Mots clés

About PWUD
Mental health